Auteur/autrice : jberthold

BRENUS PHARMA

by jbertholdin Biotech, Pharma

BRENUS PHARMA

About the company

Despite therapeutic advancements, fighting cancer requires new allies. Cancer cells can adapt themselves under therapeutic pressure and express tumor antigens that hide from our immune system’s surveillance. This mechanism leads to treatment failure of 90% of patients with solid tumors (16 million in 2022).

Brenus Pharma is a French clinical-stage biotech developing a pioneering discovery platform Stimulated-Tumor-Cell (STC) leading the path of a new generation of immunotherapies. STC doesn’t just fight cancer as it is today; it anticipates how cancer will evolve tomorrow, training the patient’s immune system to recognize and destroy tumors, even as they change.

Brenus Pharma is on the brink of a breakthrough and will start its First in Human study in 2024 in colorectal cancer, killing 9.7 million of patient per year.
They are building a strong portfolio in solid tumors, leveraging our patented STC platform, and surpassing other approaches to change a paradigm in oncology.

About the solution

The STC Platform mimics patient’s relapsing conditions in vitro to produce next-generation immunotherapies educating patient’s immune system against tumor evolution and mechanisms of relapse.

Thanks to their unique mode of production, the STCs will educate the immune system to the largest number of specific targets of interest, validated with multi-omics analysis and patient’s biopsies databases. Thanks to the standardization of the platform, access to the drug will not be limited by production or price, and they can also anticipate synergies with other innovations (ADC, ICP).

Their first candidate, STC-1010, is focused on metastatic colorectal cancer (mCRC) an urgent unmet need.

Website
Key information

–  Therapeutic areas: Primary TA: Metastatic Colo Rectal Cancer (mCRC)
Secondary TA : Pancreas Cancer, Liver cancer, Ovarian Cancer, Solid Tumors

–  Based in: Lyon & Clermont-Ferrand (FRANCE)

–  Employees: 11 – 50

–  Created in: 2020

PHOST’IN THERAPEUTICS

by jbertholdin Biotech, Pharma

PHOST’IN THERAPEUTICS

About the company

Phost’in develops First-in-Class N-glycosylation inhibitors for the treatment of cancers and fibrosis (First-in-Human currently on-going in Europe for the first program).

About the solution

PhOx430, First-In-Class selective GnT-V inhibitor, now evaluated in Ph.I in patients with Advance Solid Tumors.

Website
Key information

–  Therapeutic areas: Oncology, Fibrosis

–  Based in: Montpellier (FRANCE)

–  Employees: 1-10

–  Created in: 2014

TEMISIS

by jbertholdin Biotech, Pharma

TEMISIS

About the company

Temisis, a preclinical-stage biotechnology company, is developing innovative therapeutics for patients living with chronic inflammatory and auto-immune diseases, with a primary focus on psoriasis. Temisis’ lead drug candidate, TEM2085, is a first-in-class oral small molecule targeting NFKBIZ signaling, which is a key pro-inflammatory gene involved in the pathogenesis of a variety of immunological indications.

They believe that TEM2085, exhibiting significant efficacy in animal models of immuno-inflammatory diseases and resulting from our drug discovery platform, has the potential to show comparable efficacy to biologics which have demonstrated to date the greatest therapeutic benefit in this area. Temisis’ short-term goal is to move TEM2085 through final stages of preclinical development for clinical evaluation.

About the solution

Temisis’ lead drug candidate, TEM2085, is a first-in-class oral small molecule targeting NFKBIZ signaling, which is a key pro-inflammatory gene involved in the pathogenesis of a variety of immunological indications. In vitro, TEM2085 shows, at low concentrations, significant inhibition of NFKBIZ expression induced by IL-17/TNFα in keratinocytes. In vivo, TEM2085 has demonstrated in rodent models, at a lower dose, greater therapeutic benefit than the TYK2 inhibitor deucravacitinib against psoriasis and strong protection against ulcerative colitis. By targeting NFKBIZ signaling, TEM2085 and its analogues have the potential to address various immunological disorders.

Website
Key information

–  Therapeutic areas: Inflammatory diseases, Auto-immune diseases

–  Based in: Vandœuvre-lès-Nancy (FRANCE)

–  Employees: 1-10

–  Created in: 2017

PRODUCT LIFE GROUP

by jbertholdin Biotech, Pharma

PRODUCT LIFE GROUP

About the company

PLG provides Product Development consulting services covering:

– Regulatory science and global development strategy (incl. consultations with agencies)

– Full CMC development and related QA & QP services (incl. interaction with CDMOs, EU batch certification and release)

– Nonclinical development strategy consulting & operational support

– Clinical development strategy consulting & operational support

– Market access at global and local level

– Regulatory procedures and documents: briefing packages, ERA, PDE, ODD, PIP, biowaivers CCDS / CCSI…

– Medical writing & publishing: IND / CTA, (A)NDA / BLA, all eCTD modules, study reports

– Clinical trials applications management

– Marketing Authorization procedures management (EU CP / DCP / MRP, US NDA / BLA)

About the solution

The team offers flexible consulting approach tailored to Biotechs regulatory needs and works in close collaboration with their partners. Their global network of senior regulatory & CMC experts allows to support all modalities, therapeutic areas and interact with all major regulatory agencies.

Website
Key information

–  Therapeutic areas: Consulting services covering all therapeutic areas and drug modalities

–  Based in: Headquarter in Courbevoie (FRANCE) DSI Harleysville (US Affiliate)

–  Employees: 500+

–  Created in: 1993

BRAINTALE

by jbertholdin Digital Health, Medtech

BRAINTALE

About the company

BrainTale is an innovative medtech company deciphering white matter to enable faster drug development and better brain care with clinically validated prognostic solutions. With non-invasive, sensitive and reliable measurements of white matter microstructure alterations, BrainTale offers a digital biomarkers platform to support clinical development programs and decision-making in clinical routine.

BrainTale enables the identification of patients at risk, early diagnosis and monitoring of disease progression and the effectiveness of treatments in neurology, in particular for demyelinating diseases such as Multiple Sclerosis and neurodegenerative diseases such as Alzheimer’s Diseases. Based on more than 15 years of research and development, BrainTale’s products are developed to meet the medical needs and expectations of pharma companies and healthcare professionals for the benefit of patients. 

About the solution

BrainTale’s solutions enable access to diffusion MRI markers for drug development and patient care, through a unique technology that enables calibration and standardization of MRI diffusion parameters in a multidevice and multicenter setting. Thus, BrainTale offers quantification of white matter tissue, especially fiber density, axonal degeneration and myelin content, with unlimited potential to support clinical development programs through accurate patient selection and stratification at inclusion, and evaluation of treatment efficacy with highly sensitive and robust biomarkers.

Website
Key information

–  Therapeutic areas: Neuroscience, Neurology, Alzheimer’s Disease, Multiple Sclerosis, Traumatic Brain Injury, Rare demyelinating diseases

–  Based in: Paris & Strasbourg (FRANCE)

–  Employees: 11 – 50

–  Created in: 2018

ETAP-LAB

by jbertholdin Institutions, Service Providers & others

ETAP-LAB

About the company

ETAP-Lab is a preclinical CRO renowned for its expertise in the fields of dermatology, neurology, cardiology and gastroenterology. It assesses the effectiveness of drug candidates and medical devices.

Founded in 1991, ETAP-Lab has now worked with 150 companies ranging from small biotechs to large pharmaceutical groups, both in France and further afield. Ever since the company’s earliest days, ETAP-Lab models have consistently offered high translational value associated with relevant protocols. Mainly comprised of scientific experts, our team analyses client requirements, offering guidance and advice in the development of a tailor-made solution.

ETAP-Lab studies are conducted to exacting quality standards, ensuring the reproducibility, transparency and traceability of tests while maintaining responsiveness and offering regular dialogue with our project managers.

About the solution

ETAP-Lab can fast-track your pipeline with preclinical excellence having high predictability level through in vitro and in vivo testing and rodent behavioural analysis:

– DERMATOLOGY: Wide portfolio of original inflammatory (psoriasis, atopic dermatitis) and wound-healing in vivo models.

– CARDIOLOGY: In-depth in vivo studies of major cardiovascular diseases like Pulmonary Arterial Hypertension, Ischemia Reperfusion, and Heart failures.

– NEUROLOGY: Original and translational in vivo and in vitro models of Stroke and neurodegenerative diseases like Alzheimer’s and Parkinson’s models.

– GASTROENTEROLOGY: In vivo models of gastrointestinal disorders like irritable bowel syndrome (IBS) and traveler’s diarrhea. Expertise in metabolic disturbances such as diabetes, obesity, and malnutrition.

Website
Key information

– Therapeutic areas: Dermatology, Neurology, Cardiology, Gastroenterology, Metabolism

– Based in: Production sites in France

– Employees: 11 – 50

– Created in: 1991

CLINSEARCH

by jbertholdin Institutions, Service Providers & others

CLINSEARCH

About the company

ClinSearch is a full service European CRO, established in 1999, offering clinical research and medical evaluation services throughout Europe, as well as the Middle East and the United States.

They have conducted hundreds of studies, from phase I to IV studies, early access programs, post-marketing studies, RWE, PASS, PAES, database analyses and medico-economic studies, involving 1 patient up to 220,000 subjects.
Their customers include global and local medical device, biotechnology and pharmaceutical companies, as well as public health institutions.

About the solution

Full service offering from A to Z: methodological input to study design through to peer-reviewed publications, passing via in-house development of sophisticated healthcare tools (EDC, ePRO, …).

The in-house team of over 70 people work from our headquarters in Malakoff (France), but hail from ~15 different countries and speak over 10 languages, and are trained to a high standard (MD, PhD, PharmD, MS, MPH …).

Website
Key information

–  Therapeutic areas: Addiction, Aesthetics, Algorithm, Software, Cardiovascular, Dermatology, Fertility, Immunology, Infectiology, Hematology, Neurology, Neuromuscular, Neurovascular, Nursing care, Orthopedic, Oncology, Rheumatology, Rare diseases, Respiratory, Surgery, Urology

–  Based in: Boston (USA)

–  Employees: 51-200

–  Created in: 1999

ANTABIO

by jbertholdin Biotech, Pharma

ANTABIO

About the company

Antabio is a privately-held clinical stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments of drug-resistant infections due to WHO critical priority pathogens, with a particular focus on life-threatening respiratory infections.

Antabio has one of the best teams in the industry featuring former management and executives from Novexel, GSK, Merck and AstraZeneca with track-records in anti-infective drug development, licensing and M&A. The company has an impressive track-record in attracting non-dilutive funding, including multi-million € awards from the Wellcome Trust, CARB-X, the French Government (ARPEGE), and the European Union (EIC Accelerator).

About the solution

Antabio’s portfolio includes MEM-ANT3310, which combines the well-known carbapenem meropenem (MEM) with ANT3310, Antabio’s breakthrough serine-beta-lactamase (SBL) inhibitor. MEM-ANT3310 provides a unique coverage of priority Gram-negative pathogens frequently encountered in life-threatening infections such as Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP). Phase 1a clinical study has recently been completed.

Their portfolio also includes ANT3273, a groundbreaking (novel class, novel mode of action) inhaled drug targeting the LasB elastase of Pseudomonas aeruginosa (PA), a key virulence factor associated with increased lung pathology severity and worse outcomes in PA-infected patients, such as bronchiectasis, cystic fibrosis, asthma and COPD.

Website
Key information

–  Therapeutic areas: Infectious diseases, Urinary Tract Infection, Respiratory Tract Infection, Multidrug resistant infection, Bacterial infection, Gram negative bacterium infection, Lung infection, Bacterial Pneumonia, Bronchiectasis, Cystic Fibrosis

–  Based in: Labège (FRANCE)

–  Employees: 11 – 50

–  Created in: 2009

TRUFFLE CAPITAL

by jbertholdin Biotech, Pharma

TRUFFLE CAPITAL

About the company

For 20 years, Truffle Capital has been financing innovations, growing and empowering technology leaders in healthcare & finance.

Website
Key information

–  Therapeutic areas: Infectious diseases, oncology, rheumatalogy, joint diseases, Transplants

–  Based in: Paris (FRANCE)

–  Employees: 11 – 50

–  Created in: 2001

QUBIT PHARMACEUTICALS

by jbertholdin Biotech, Pharma

QUBIT PHARMACEUTICALS

About the company

Qubit Pharmaceuticals specializes in ‘in silico’ drug discovery for challenging disease targets, including those currently viewed as being ‘undruggable’ using small molecules by the pharmaceutical community.

Their approach is using proprietary molecular simulation and quantum-physics based modeling technology built from over 30 years of research from Pr. Jay W. Ponder’s lab in Washington University in St. Louis, Pr. Pengyu’s Ren lab in University of Texas at Austin, Pr. Jean-Philip Piquemal and Docteur Louis Lagardère at Sorbonne University, and Pr. Matthieu Montes at the Conservatoire national des arts et métiers (Cnam).

About the solution

Qubit Pharma uses a hybrid approach leveraging the power of both classical and quantum computing to produce more effective and safer drugs and is designed to significantly reduce the time and investment needed to discover new drug candidates by a factor of 10.

Today, the focus lies on solving cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. Qubit Pharma is well positioned to become one of the first companies to show a practical quantum advantage in drug discovery.

In less than 18 months, Qubit Pharmaceuticals grew its drug discovery portfolio to 6 programs in oncology & inflammation leveraging its proprietary drug discovery platform, Atlas.

Qubit Pharma out-licenses and co-develops compounds with pharmaceutical partners. Once our candidate compounds have achieved advanced stages of drug development, we may seek out-licensing and other strategic alliances for further development, manufacturing, and launching the drug as a commercial pharmaceutical product in selective geographies.

Website
Key information

–  Therapeutic areas: Solving cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases

–  Based in: Paris (FRANCE) & Boston (USA)

–  Employees: 51 – 200

–  Created in: 2020